In the United States, pre-transfusion testing of potential recipients is required before any routine transfusion and is an essential step in maximizing safe and effective transfusion outcomes for recipients. The Mayo Clinic Hospital – Rochester Pre-Surgical Sample (PSS) Program allows patients who are scheduled for elective surgery to have their samples collected for pre-transfusion testing. This advanced testing allows ample time to investigate and resolve any serologic problems due to unexpected red-cell-directed antibodies. The efforts and processes implemented by the PSS Program were recently highlighted in the journal Transfusion.
Amyloidosis derived from leukocyte cell-derived chemotaxin 2 (ALECT2), a newly recognized form of amyloidosis, has already been established as a frequent form of systemic amyloidosis in the United States, with predominant involvement of the kidney and liver. Mayo Clinic researchers reviewed recent Mayo Clinic and non-Mayo Clinic studies to establish the clinicopathologic characteristics, incidence, and outcome of amyloidosis derived from ALECT2.
Everolimus is an oral agent that targets the mTOR pathway. Mayo Clinic researchers, first author Mamta Gupta, conducted a study published in the journal Blood to investigate mTOR pathway activation in T cell lymphoma (TCL) cell lines and assess anti-tumor activity in patients with relapsed/refractory TCL in a Phase II trial.
In a study published in the journal Methods, Mayo Clinic researchers John Mills, Ph.D., David Murray, M.D., Ph.D., and David Barnidge, Ph.D., established a mass spectrometry-based method to assign molecular mass to the immunoglobulin light chain of the M-protein and used it to detect the presence of M-proteins.
Renal dysfunction occurs in up to one-half of patients with multiple myeloma (MM). In the Journal of the American Society of Nephrology, Mayo Clinic researchers describe a case of crystalglobulin-induced nephropathy and discuss its pathophysiology and the differential diagnosis of paraprotein-induced crystalline nephropathy.
Mayo Clinic researchers recently developed an RT-PCR assay along with a break-apart FISH assay that can diagnose fibrolamellar carcinoma 100 percent of the time. The assays can detect the novel fusion at the transcriptional and genomic level, respectively.
Dabigatran etexilate (Pradaxa), an oral, direct thrombin inhibitor, was approved in October 2010 by the U.S. Food and Drug Administration (FDA) for prevention of stroke and thrombosis in patients with nonvalvular atrial fibrillation (AF). In a recent article in Clinical Chemistry, Mayo Clinic researchers, Hemamalini Ketha, Ph.D., and John Mills, Ph.D., discuss whether dabigatran is a risk to patient safety.
Ovarian cancer is often sensitive to platinum-based chemotherapy, causing patients to develop resistance. Oncolytic measles virus (MV) expressing the sodium iodide symporter gene (MV-NIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Mayo Clinic researchers conducted a study in the Cancer Research journal to determine the effect of MV-NIS in patients with treatment-resistant ovarian cancer.
Richter syndrome is defined as the transformation of chronic lymphocytic leukemia (CLL) to a more aggressive lymphoma. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has shown significant efficacy in relapsed/refractory CLL. Mayo Clinic researchers conducted a study in Blood to determine the efficacy of ibrutinib in the treament of richter syndrome.
Hyperammonemia syndrome is a fatal complication affecting immunosuppressed patients. Mayo Clinic researchers conducted a study in Science Translation Medicine to assess if the systemic infection with Ureaplasma species might pose a unique challenge to human ammonia metabolism by liberating free ammonia resulting in the hyperammonemia syndrome.
Targeted next-generation sequencing has the potential to stratify a tumor by molecular subtype and aid the development of a biomarker profile for prognostic risk stratification and theranostic potential. Mayo Clinic researchers conducted a study in Gastrointestinal Endoscopy to assess the frequency and distribution of pathogenic alterations in malignant lymph node cytology specimens.
Mayo Clinic researchers conducted a study, recently published in Blood, to characterize the role of IRF4 in peripheral T-cell lymphoma cells and to develop a clinically feasible strategy to target those mechanisms.
A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients’ gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.